BSG and plasma cell myeloma: Then, CD147’s overexpression can be used as a biomarker in HMs [14,15,16,17,18,20], and its protein partners represent a potential therapeutic target in the treatment of hematologic malignancies for the development of new therapies aimed at identifying and manipulating specific metabolic vulnerabilities of the different main groups, leukemia, lymphoma, and multiple myeloma, of HMs that support neoplastic cells proliferation.